Background
==========

The emergence and spread of MDR-TB and extensively drug-resistant tuberculosis (XDR-TB) posed a severe impediment for the prevention and control of tuberculosis (TB) transmission \[[@B1]-[@B3]\]. According to the World Health Organization (WHO) \[[@B4]\], there were about 650,000 cases of MDR-TB present in the world in 2010, and was estimated that about 9% of these cases of XDR-TB. Annually, about 440,000 were infected with MDR-TB and 150,000 died of MDR-TB. Due to the severity of MDR-TB, the WHO convened a international meeting focused on MDR-TB in April 2009 in Beijing, China, urging member states to take detailed and effective action in diagnosing and treating M/XDR-TB \[[@B4]\]. Another survey of WHO in 2010 showed that the estimated MDR-TB among the notified re-treatment cases (n = 7,795) was 2,200 (28%) \[[@B5]\]. So the Global Plan to STOP TB (2006--2015) proposed that by 2015 all countries should carry out DST for all re-treatment tuberculosis patients \[[@B6]\]. In order to control the MDR-TB,it was important for re-treatment PTB patients to develop a rapid, reliable and high-throughput drug susceptibility testing to obtain first- and second-line anti-tuberculosis drugs susceptibility result simultaneously, as it was essential to decrease patient morbidity and mortality as well as treatment-associated costs.

At present, the conventional drug susceptibility testing methods for *M.tuberculosis* were the bacteriological methods performed by culture in liquid or on solid media with highly sensitive and specific to most anti-TB drugs. However, these methods were laborious, time-consuming and could not provide rapid detection for clinical practice. Consequently, the rapid molecular diagnostic methods which performed within 1 or 2 days would be helpful for shortening the detection time.

Spontaneous chromosomal mutations were the genetic basis for drug resistance in *M. tuberculosis*\[[@B7],[@B8]\]. At present, RIF resistance was almost entirely associated with the mutation of an 81-bp region of the *rpoB* gene, the RIF resistance determining region (RRDR) \[[@B9]-[@B11]\]. The resistance to INH, EMB, SM, OFL and AMK was primarily found in mutations in the *katG*, *embB, rpsl, gyrA* and *rrs* genes, respectively \[[@B8],[@B12]-[@B16]\]. All these resistance-associated mutations were predominantly found in a short region or a position in *M. tuberculosis* genome and could be considered as the beacons of molecular drug susceptibility testing. Currently, the WHO endorsed some molecular methods to detect individual anti-TB drugs susceptibility by detecting gene mutations associated with drug resistance, such as Xpert MTB/RIF \[[@B17]\] and GenoType MTBDR \[[@B18]\] methods.

Pyrosequencing was a DNA sequencing technique that was based on the detection of the pyrophosphate released during DNA synthesis \[[@B19]-[@B21]\], and was well suitable for large-scale screening for a short length DNA fragment. At present, pyrosequencing had become a novel approach for the detection of TB infection and tuberculosis resistance \[[@B22]-[@B25]\]. Compared to GenoType MTBDR method, pyrosequencing was more accurate and easier to handle. Compared to Xpert MTB/RIF method, pyrosequencing could detect more drugs resistance. In this study, our aim was to establish a rapid molecular method for the detection of tuberculosis resistance by pyrosequencing technology and to evaluate its clinical value in re-treatment pulmonary tuberculosis patients.

Methods
=======

Ethics considerations
---------------------

The Shanghai Pulmonary Hospital Affiliated to Tongji University School of Medicine Ethics Committee approved the research protocols (permit number: 2010--034). The informed consent was obtained from each patient who was treated in accordance with the Helsinki Declaration on the participation of human subjects in medical research.

Source of clinical isolates and sputum samples
----------------------------------------------

A total of 205 clinical *M.tuberculosis* isolates and 24 sputum samples were obtained from PTB patients in Shanghai Pulmonary Hospital from January 2010 to March 2011. All the sputum specimens were smear-positive and were classified according to an acid-fast bacillus (AFB) staining scale as 1+ (1 case), 2+ (3 cases), 3+ (12 cases) and 4+ (8 cases). All of the samples were identified as *M.tuberculosis* by Bactec MGIT 960 culture, Ziehl-Neelsen staining and standard biochemical identification testing \[[@B26]\] and all of the samples were collected from re-treatment PTB patients. The re-treatment PTB definition was a patient who failed the standard initial tuberculosis treatment regimen, who relapsed after initial treatment with a standard or non-standard tuberculosis regimen. In addition, 10 clinical isolates, including 3 isolates susceptibility and 2 isolates resistant to RIF, INH, EMB, SM, AMK and OFL and the other 5 isolates resistant to four or five drugs, were collected from Shanghai Pulmonary Hospital. These isolates were sequenced on an ABI 3730xl DNA Analyzer by the Sangon Engineering Company (Shanghai, China) to obtain the sequence of *rpoB*, *katG, embB, rrs, gyrA* and *rpsl* genes. *M.tuberculois* standard strain (H37Rv, ATCC25618) was purchased from the National Culture Collection.

Specimen processing and genomic DNA extraction
----------------------------------------------

For *M.tuberculosis* isolates, genomic DNA extraction was performed as described previously \[[@B22]\]. For sputum samples, prior to DNA extraction, each sputum sample was decontaminated with an equal volume of 2% NaOH and 0.5% NALC, incubated at room temperature for 20 min, neutralized with 67 mM phosphate buffer (pH 6.8) and then centrifuged at 3,300 × *g* for 20 min at 4°C. The processed sediment was washed once using a sterile 0.9% NaCl solution and re-suspended in 1.0 ml sterile 0.9% NaCl solution. Two separate 500 μl aliquots were prepared in 1.5 ml tubes for the DNA extraction and Bactec MGIT 960 culture. The 500 μl aliquots for the DNA extraction were inactivated and lysed for 30 min at 85°C and DNA extraction was performed as described above for the extraction of clinical isolates previously. The concentration of the genomic DNA was measured by the Biophotometer (Eppendorf).

Design of primers and PCR amplification
---------------------------------------

Regions of the *rpoB*, *katG, embB, rrs, gyrA* and *rpsl* genes were amplified by conventional PCR. Amplification and sequencing primers for pyrosequencing were designed with PSQ assay design software (Biotage, Inc., Charlottesville, VA). Primers and amplicon sizes were presented in Table [1](#T1){ref-type="table"}. Amplification reaction was performed in a final volume of 50 μl consisting of 0.5 μl 10 × PCR buffer, 0.2 mM deoxynucleotide triphosphates (Takara), 1U Taq DNA polymerase (Takara), 200 nM of each primer, and 10 ng of DNA. Thermo-cycling conditions were as follows: 95°C for 3 min followed by 50 cycles of 30 s at 95°C, 30 s at respective annealing temperature, 30 s at 72°C and final elongation at 72°C for 10 min.

###### 

Primers and thermo-cycling conditions of the pyrosequencing assays

  **Drug**   **Gene**   **Primer**     **Sequences (5'---3')**   **Annealing temperature (°C)**   **Size (bp)**   **Target loci**
  ---------- ---------- -------------- ------------------------- -------------------------------- --------------- -----------------
  RIF        *rpoB*     Forward        GTCCGGGAGCGGATGACCACCC    65                               204             RRDR
                        Reverse\*      GCTCACGTGACAGACCGCCG                                                        
                        Sequencing 1   GCGATCAAGGAGTTC                                                             
                        Sequencing 2   TCATGGACCAGAACAA                                                            
  INH        *katG*     Forward        AGATGGGCTTGGGCTGGA        61                               133             315
                        Reverse\*      TAGCCGTACAGGATCTCGAGGA                                                      
                        Sequencing     CCGGTAAGGACGCGA                                                             
  SM         *rpsl*     Forward\*      CAAGGGTCGTCGGGACAAGA      61                               299              
                        Reverse        TCTTGACACCCTGCGTATCC                                                        
                        Sequencing 1   CGCCGAGTTCGGCTT                                                            43
                        Sequencing 2   CACACCAGGCAGGTC                                                            88
  EMB        *embB*     Forward        ACGACGGCTACATCCTGG        61                               110             306
                        Reverse\*      GTTGTAATACCAGCCGAAGGGA                                                      
                        Sequencing     CGACGGCTACATCCTG                                                            
  OFL        *gyrA*     Forward        TTCGATTCCGGCTTCCGCCC      61                               192             QRDR
                        Reverse\*      TGGGTCATTGCCTGGCGAGC                                                        
                        Sequencing     TACCACCCGCACGGC                                                             
  AMK        *rrs*      Forward        TCCTTAAAAGCCGGTCTCAGTTC   61                               239             1401
                        Reverse\*      TCCGGTACGGCTACCTTGTTA                                                       
                        Sequencing     CTTGTACACACCGCC                                                             

\*: The primer was labeled at the 5-end with biotin.

Protocols of pyrosequencing
---------------------------

Pyrosequencing was performed using PyroMark 96MA instrument (Qiagen, formerly Biotage AB, Inc.). PSQ 96MA system had two modes to detect gene mutation. One was dedicated sequence analysis (SQA) Software which could give true sequence information about 50 bases. The other was single-nucleotide polymorphism (SNP) Software which could support fast genotyping results.

To determine the optimal mutation detection modes for *rpoB*, *katG, rpsl, embB, gyrA* and *rrs* genes, 10 collected *M.tuberculosis* clinical isolates with known sequence by Sanger Sequencing were detected gene mutations by pyrosequencing with both SQA mode and SNP mode. Then the results from pyrosequencing were compared with the gold standard "Sanger sequencing" results by the Identifire software. The pyrosequencing results were considered valid if the pyrosequencing results were consistent with Sanger Sequencing results. The detection mode and the nucleotide dispensation order of pyrosequencing were considered optimum if pyrosequencing results were valid and the assay could consume less detection time and reagent. The conditions were presented in Table [2](#T2){ref-type="table"}.

###### 

**Optimum conditions for detection mutation of*rpoB*,*katG, gyrA, rrs, embB*and*rpsl*genes by pyrosequencing**

  -------------------------------------------------------------------
  **Loci**   **Detection mode**   **Nucleotide dispensation order**
  ---------- -------------------- -----------------------------------
  *rpoB*     SQA mode             RRDR mutation: 16(AGCT)

  *katG*     SNP mode             315 mutation: GTCACAGTCTG

  *rpsl*     SNP mode             43 mutation: CGATACGAGT\
                                  88 mutation: CGATGCACGC

  *embB*     SNP mode             306 mutation:TGCAGTGACGCGCAGT

  *gyrA*     SQA mode             QRDR mutation: 12(GACT)

  *rrs*      SNP mode             1401 mutation: TCGTCAGTCAGTCAT
  -------------------------------------------------------------------

The gene mutations of 205 *M.tuberculosis* clinical isolates and 24 sputum samples were detected by pyrosequencing under the optimal conditions as considered above.

In brief, pyrosequencing method included preparation of the template and sequencing reaction. Firstly the PCR amplification product immobilized on the streptavidin-coated sepharose beads (GE Healthcare, Uppsala, Sweden) was converted into single-stranded DNA template and purified with a vacuum preparation tool. Then a sequencing primer was subsequently annealed to the template. Pyrosequencing was performed in an automated PyroMark 96MA instrument according to the manufacturer's instructions. For the SQA mode detection, a PyroMark Gold Q96 SQA reagents (Qiagen, 972812) and cyclic dispensation of the nucleotide was used. The resultant sequences were compared with a database containing sequences of known mutations by mean of the Identifire software. The mutation types and loci were determined using alignment with the sequence results of *M.tuberculosis* H37Rv (ATCC25618, and GenBank accession no. NC_000962) \[[@B27]\]. For the SNP mode, the genotyping results were directly obtained by using the PyroMark Gold Q96 reagents (Qiagen, 972804). During pyrosequencing testing, amplified H37Rv genomic DNA was employed as a control. Some new nucleotide sequences were submitted to the Genbank (Accession numbers: KJ659894, KJ659895, KJ659896, KJ659897, KJ659898, KJ659899, KJ659900, KJ659901, KJ659902).

DST of *M.tuberculosis* by the Bactec MGIT 960 system
-----------------------------------------------------

DST was performed using the Bactec MGIT 960 mycobacterial detection system. Drug concentrations used in the MGIT 960 system were: RIF: 1.0 μg/ml, INH: 0.1 μg/ml, SM: 1.0 μg/ml, EMB: 5.0 μg/ml, OFL: 2.0 μg/ml and AMK: 1.0 μg/ml \[[@B28]\].

Statistical analysis
--------------------

Data analysis was carried out using Stata version 9 (Statacorp, Texas, USA). The sensitivity, specificity and accuracy were calculated for pyrosequencing results versus Bactec MGIT 960 system results. The Bactec MGIT 960 system results were considered as the gold standard of DST for comparison with the results obtained from pyrosequencing. The agreement between the pyrosequencing results and Bactec MGIT 960 results was analyzed using Kappa value.

Results
=======

DST using Bactec MGIT 960 system
--------------------------------

DST of RIF, INH, SM, EMB, OFL and AMK was detected by Bactec MGIT 960 system. Of the 229 re-treatment PTB patients samples, 89.5% cases were identified resistant to at least one of the tested drugs, above 50% cases were resistant to four or five tested drugs and 6.6% cases were resistant to only one drug.

Pyrosequencing results for the detection of gene mutations
----------------------------------------------------------

All of the 205 clinical isolates and 24 sputum samples, pyrosequencing identified 10 kinds of codon involving in 39 types of mutations in RRDP of the *rpoB* gene, and 60.4% (110/182) and 20.3% (37/182) of the RIF-resistant clinical samples had a mutation at the codon 531 and 526, respectively, in Table [3](#T3){ref-type="table"}. The 74.2% (141/190) of the INH-resistant clinical samples had a mutation at codon 315 in the *katG* gene. No mutation in *katG* S315 was found in INH-susceptible clinical samples. The 65.4% (100/153) and 11.8% (18/153) of the SM-resistant clinical samples had a mutation at the codon 43 and 88, respectively, in the *rpsl* gene. The 55.5% (76/137) of the EMB-resistant clinical samples had a mutation at codon 306 in the *embB* gene. There were four kinds of codons including 12 types of mutations in the regions of the quinolone resistance-determining regions (QRDR) of the *gyrA* gene, and 62% (88/142) of the OFL-resistant clinical samples had a mutation at codon 94. The 77.3% (34/44) of the AMK-resistant clinical samples showed a mutation in position 1401 in the *rrs* gene, and no mutation in this position was found in AMK-susceptible clinical samples. Mutations of the *katG*, *embB*, *rrs*, *gyrA* and *rpsl* genes were identified by pyrosequencing shown in Table [4](#T4){ref-type="table"}. The detailed information of sequences were provided in the Additional file [1](#S1){ref-type="supplementary-material"}

###### 

**Mutations of the*rpoB*gene identified by pyrosequencing in clinical isolates and sputum samples**

  **Amino acid change(s)**   **Codon change(s)**           **BACTEC MGIT 960 tests**   
  -------------------------- ----------------------------- --------------------------- ----
  L511P                      CTG/CCG                       1                           1
  Q513H                      CAA/CAC                       1                            
  D516N                      GAC/AAC                       1                            
  D516A                      GAC/GCC                       1                            
  D516G                      GAC/GGC                       3                            
  D516V                      GAC/GTC                       5                            
  D516Y                      GAC/TAC                       1                           1
  D516F                      GAC/TTC                       1                            
  N518S                      AAC/AGC                       1                            
  H526N                      CAC/AAC                       4                            
  H526Q                      CAC/CAG                       1                            
  H526R                      CAC/CGC                       2                            
  H526D                      CAC/GAC                       9                            
  H526Y                      CAC/TAC                       6                            
  H526C                      CAC/TGC                       5                            
  H526F                      CAC/TTC                       1                            
  S531T                      TCG/ACG                       2                            
  S531Y                      TCG/TAT                       2                            
  S531W                      TCG/TGG                       5                            
  S531L                      TCG/TTG                       92                           
  L533P                      CTG/CCG                       1                            
  L533R                      CTG/CGG                       4                            
  Q510H + H526Y              CAG/CAC + CAC/TAC             1                            
  L511P + D516G              CTG/CCG + GAC/GGC             1                            
  L511P + Q513P              CTG/CCG + CAA/CCA             1                            
  L511P + D516G + N518S      CTG/CCG + GAC/GGC + AAC/GAC   1                            
  N518S + H526P              AAC/AGC + CAC/CCC             1                            
  S512T + D516G              AGC/ACG + GAC/GGC             1                            
  D516A + L533P              GAC/GCC + CTG/CCG             1                            
  H526N + L533P              CAC/AAC + CTG/CCG             1                            
  H526Q + L533P              CAC/CAG + CTG/CCG             1                            
  H526Y + S531T + L530R      CAC/TAC + TCG/ACG + CTG/CGT   1                            
  L511P + S531L              CTG/CCG + TCG/TTG             1                            
  D516A + S531L              GAC/GCC + TCG/TTG             1                            
  D516V + S531L              GAC/GTC + TCG/TTG             1                            
  S531L + L533R              TCG/TTG + CTG/CGG             1                            
  H526D + L533R              CAC/GAC + CTG/CGG             1                            
  H526Y + L533R              CAC/TAC + CTG/CGG             1                            
  S531L + L533S              TCG/TTG + CTG/TCG             2                            
  WT                                                       12                          45
  Fail                                                     3                            

R: resistance; S: susceptibility; WT: wild type.

###### 

**Mutations of the*katG, embB, rrs, gyrA*and*rpsl*genes identified by pyrosequencing in clinical isolates and sputum samples**

  **Drugs**   **Genes**   **Amino acid change(s)**   **Codon change(s)**   **Nucleotide change**    **BACTEC 960 tests**  
  ----------- ----------- -------------------------- --------------------- ----------------------- ---------------------- -----
  INH         *katG*                                                                                                         
                          S315T                      AGC/ACC                                                133              
                          S315N                      AGC/AAC                                                 5               
                          S315T                      AGC/ACA                                                 3               
                          WT                                                                                 46            39
                          Fail                                                                               3               
  SM          *rpsl*                                                                                                         
                          K43R                       AAG/AGG                                                100             2
                          K88R                       AAG/AGG                                                 18             1
                          WT                                                                                 32            71
                          Fail                                                                               3              2
  EMB         *embB*                                                                                                         
                          M306I                      ATG/ATA                                                 17             4
                          M306I                      ATG/ATC                                                 2              2
                          M306I                      ATG/CTG                                                 7              2
                          M306V                      ATG/GTG                                                 50             4
                          WT                                                                                 57            80
                          Fail                                                                               4               
  OFL         *gyrA*                                                                                                         
                          G88A                       GGC/GCC                                                 1               
                          G88C                       GGC/TGC                                                 2               
                          A90V                       GCG/GTG                                                 22              
                          S91P                       TCG/CCG                                                 8              1
                          D94N                       GAC/AAC                                                 5               
                          D94H                       GAC/CAC                                                 3               
                          D94A                       GAC/GCC                                                 18              
                          D94G                       GAC/GGC                                                 54              
                          D94Y                       GAC/TAC                                                 5               
                          A90V + D94N                GCG/GTG + GAC/AAC                                       1               
                          A90V + D94G                GCG/GTG + GAC/GGC                                       1               
                          A90V + D94Y                GCG/GTG + GAC/TAC                                       1               
                          WT                                                                                 19            86
                          Fail                                                                               2               
  AMK         *rrs*                                                                                                          
                                                                           A1401G                            34              
                                                                           WT                                10            178
                          Fail                                                                                              7

The performance of pyrosequencing for the detection of TB resistance
--------------------------------------------------------------------

Compared with Bactec MGIT 960 method, pyrosequencing showed higher sensitivity and specificity in RIF, OFL, AMK and SM than in INH and EMB. The detection of EMB resistance showed the lowest sensitivity among six drugs not only in clinical isolates (58.7%) but also in sputum samples (41.7%). The INH and AMK showed the highest specificity (100%) in all the detecting drugs and samples. These results were present in Table [5](#T5){ref-type="table"}.

###### 

Comparison of pyrosequencing and Bactec MGIT 960 DST

  **Drugs and specimen**   **Pyro. methods**    **No. of samples by Bactec 960 method**   **Mean% (95% CI)**                                  
  ------------------------ ------------------- ----------------------------------------- -------------------- ----------- ------------ ------ ------
  RIF                      R                                      152                             1              94.4         97.6      95.0  0.86
                           S                                       9                              40           89.7-97.0   87.4-99.6           
  INH                      R                                      128                             0              75.3         100       79.2  0.49
                           S                                      42                              32           68.3-81.2   89.3-100.0          
  SM                       R                                      107                             3              79.3         95.4      84.5  0.68
                           S                                      28                              62           71.7-85.2   87.3-98.4           
  EMB                      R                                      71                              10             58.7         87.7      70.3  0.43
                           S                                      50                              71           49.8-67.1   78.7-93.2           
  OFL                      R                                      108                             1              86.4         98.7      91.1  0.82
                           S                                      17                              77           79.3-91.3   93.1-99.8           
  AMK                      R                                      32                              0              82.1         100       96.5  0.88
                           S                                       7                             159           67.3-91.0   97.6-100.0          
  Sputum samples                                                                                                                               
  RIF                      R                                      15                              1              83.3         83.3      83.3  0.6
                           S                                       3                              5            60.8-94.2   43.7-97.0           
  INH                      R                                      13                              0              76.5         100       83.3  0.66
                           S                                       4                              7            52.7-90.4   64.6-100.0          
  SM                       R                                      11                              0              73.3         100       83.3  0.67
                           S                                       4                              9            48.1-89.1   70.0-100.0          
  EMB                      R                                       5                              2              41.7         81.8      60.9  0.23
                           S                                       7                              9            19.3-68.1   52.3-94.9           
  OFL                      R                                      13                              0              86.7         100       91.7  0.83
                           S                                       2                              9            62.1-96.3   70.1-100.0          
  AMK                      R                                       2                              0               40          100       87.5  0.51
                           S                                       3                              19           11.8-76.9   83.2-100.0          

CI: confidence interval.

Discussion
==========

In this study, we developed a method for detecting RIF, INH, EMB, SM, OFL and AMK resistance by the pyrosequencing technology and evaluated this method on a panel of 229 clinical samples of *M.tuberculosis*. We optimized the pyrosequencing conditions to detect drug resistance to six anti-TB drugs. In the pyrosequencing operating system,two modes, SQA and SNP, could be used, but the two modes differed in several aspects. For example, SQA mode detected a short and medium length DNA fragment, and SNP mode detected only a single base variation. In our experiments, although SQA mode could detect all 6 drugs resistance, we chose the SNP mode rather than SQA mode to detect the mutation of *katG, rpsl, embB* and *rrs* based on the below reasons. The mutations of these genes were mainly involved a few point mutations. In detection resistance of INH, only *katG* gene at codon 315 was detected; in EMB, only *embB* gene at codon 306 was detected; in SM, only *rpsl* gene at codon 44 and 88 was detected; in AMK, only *rrs* gene at nucleotide position 1401 was detected. However, for *rpoB* and *gyrA* gene, we chose the SQA mode to detect the mutation because the sequence of interesting had been highly polymorphic and a short region should be sequenced. The most important advantage for choosing the SNP mode rather than SQA mode was that the former was quicker than the latter. By SNP mode, it was possible to sequence 96 samples in approximately 15 min, while it needed 70 min by the SQA mode. Thus, the time needed by SNP mode was shorter approximately only one- fourth of the time needed by SQA mode. Another advantage with SNP mode over SQA mode was that it could greatly reduce the detection cost to be 1/3.

The traditional gold standard for detection drug resistance of tuberculosis was the bacteriological methods. Therefore, we compared the results of pyrosequencing with the Bactec MGIT 960 mycobacterial detection system. The pyrosequencing approach showed different sensitivity and specificity among six drugs. For clinical isolates, the sensitivity of pyrosequencing for detecting resistance to the six drugs ranged from 58.7% to 94.4%, and the specificity was above 87.7%.

In RIF assay, compared to Bactec MGIT 960 DST, the sensitivity and specificity of the pyrosequencing method were similar to previously reported values \[[@B29]\]. The 95.0% (192/202) of pyrosequencing results were concordant with the results of Bactec MGIT 960. Among the ten inconsistent specimens, one isolate which was RIF susceptible was resistant by prosequecing and the mutation was detected at codon Leu 511 Pro. This mutation usually occurred in RIF resistant isolates together with other mutations \[[@B29]\]; therefore this mutation alone maybe had low predictive value for RIF resistance. The other nine phenotypical RIF resistant isolates did not detect a mutation in the RRDR and it was possible that another mutations existed outside the RRDR or elsewhere in the genome.

In INH assay, the specificity was high to be 100%, whereas the sensitivity of detecting resistance to INH was much low. The relatively low sensitivity in the detection of INH resistance might be related to only *katG* 315 detected. Both *inhA* and *aphC* had also been demonstrated to confer the INH resistance \[[@B14],[@B30]\]. So these genes might increase the sensitivity when evaluated.

In SM assay, the codon 43 and 88 of *rpsl* gene were detected by pyrosequencing and showed low sensitivity. In previous report, the mutations in position 513 or 516 of *rrs* gene were correctly identified in SM-resistant clinical isolates \[[@B31]\]. Therefore, the sensitivity might increase when these genes involved.

The sensitivity and specificity of detection of EMB resistance were the lowest among six drugs, which were consistent with the previous study \[[@B32]\]. These results also suggested that codon 306 point mutation in the *embB* gene was a poor indicator of EMB resistance, and other genes, such as *embC* and *embA* might confer EMB resistance \[[@B33]\].

The high specificity of the OFL assay (98.7%) and the low sensitivity (86.4%) were analyzed here. One OFL-susceptible isolates was identified as resistant by the pyrosequencing assay because the MIC (0.5 μg/ml) for this isolate was close to the critical concentration for OFL (1.0 μg/ml). The other 17 of the 125 phenotypical OFL-resistant isolates did not detect a mutation in the QRDR of the *gyrA* gene, which might have other mutation existed other site in *gyrA* or in *gyrB* gene \[[@B34]\].

The specificity of AMK resistance was 100%, and the sensitivity was low (82.1%). The 7 of the 39 AMK-resistant isolates without a mutation at position 1401 in the *rrs* gene suggested that another mutation might exist in other site of *rrs* gene or other genes conferring AMK resistance. These results might provide the cues to further studies on AMK resistance.

In addition, we detected the resistance of 24 smear-positive sputum samples by pyrosequencing in re-treatment PTB patients, which showed that pyrosequencing approach could applied to detect smear-positive sputum specimens. Then the bacterial culture avoided by this direct examination of sputum samples, and the detecting turn-around time could greatly shorten. However, most of the samples in our study were quantified as 3+ to 4+ for acid-fast (AFB) staining, so this application could be used to study in large scale and in sputum specimen of 1+ or 2+ acid-fast (AFB) staining. The nested PCR might be essential when detected the sputum specimens with 1+ or 2 + .

Conclusions
===========

We concluded that the pyrosequencing is a rapid and high-throughput method for the detection of resistance to RIF, INH, SM, EMB, OFL and AMK in *M.tuberculosis*. Pyrosequencing can be used as a practical molecular diagnostic tool for screening and predicting the resistance for re-treatment pulmonary tuberculosis patients.
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